Skip to main content

Albert Selva O'Callaghan

I've been a doctor for over 30 years now and I work at the Vall d'Hebron University Hospital.

Institutions of which they are part

Main researcher
Systemic Diseases
Vall Hebron Institut de Recerca
Internal Medicine
General Hospital

Albert Selva O'Callaghan

Institutions of which they are part

Main researcher
Systemic Diseases
Vall Hebron Institut de Recerca
Internal Medicine
General Hospital

I've been a doctor for over 30 years now and I work at the Vall d'Hebron University Hospital.

Was born in Barcelona on May 1st, 1959. He obtained his medical degree at the University Autonomous of Barcelona in 1982, and so he did also the Doctoral Thesis at the same University in 1992. Since 2010 he is Associated Professor of Medicine, since june 2021 Full Professor. He attended to the internal resident program (MIR) at the Internal Medicine Department at Vall d’Hebron General Hospital in Barcelona from 1986 to 1990, and currently is working as a Senior Consultant and as Head at the Systemic Autoimmune Diseases Unit at the same hospital. He has been focused to the study of idiopathic inflammatory myopathy for more than 25 years and has published several relevant articles and book chapters on the field. Taking care of the patients, teaching at the University and doing research are the three main activities in regard to myositis patients he is committed to.

Research lines

Cancer and myositis. Relevance of the anti-p155 antibodies and importance of the screening for cancer by Positron Emission Tomography and Computed Tomography (PET/CT).

Anti-p155 antibodies seem to be useful for the diagnosis of paraneoplastic myopathies. We have studied their prevalence and their diagnosis value in a cohort of 137 patients with inflammatory myopathies and we have observed that they have a high negative predictive value. On the other hand, the screening by PET/TC does not contribute much to the conventional screening of cancer in these patients.

IP: Albert Selva O'Callaghan

Projects

Autoinmunitat i Malaltia Trombotica

IP: Albert Selva O'Callaghan
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2017SGR01129
Duration: 01/01/2017 - 31/12/2020

Identificación de nuevos antígenos en pacientes con miopatía inflamatoria

IP: Albert Selva O'Callaghan
Collaborators: Ernesto Trallero Araguas
Funding agency: Instituto de Salud Carlos III
Funding: 121000
Reference: PI15/02100
Duration: 01/01/2016 - 30/11/2020

Autoimmunitat i Malaltia Trombòtica (GRC)

IP: Miguel Vilardell Tarres
Collaborators: Carmen Pilar Simeón i Aznar, Roser Solans Laque, Segundo Bujan Rivas, Vicenç Fonollosa Pla, José Ordi Ros, Josefina Cortes Hernandez, Fernando Martínez Valle, Albert Selva O'Callaghan, Cristina Solé Marce
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 329
Duration: 01/01/2014 - 31/12/2016

Proteinas TIF1 y dermatomiositis paraneoplásicas

IP: Ernesto Trallero Araguas
Collaborators: Vicente García-Patos Briones, Berta Ferrer Fábrega, Albert Selva O'Callaghan, Gloria Aparicio Español
Funding agency: Instituto de Salud Carlos III
Funding: 121000
Reference: PI12/01320
Duration: 01/01/2013 - 31/12/2016

Related news

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.

The study showing how thrombocytopenia increases the risk of thrombosis in patients with antiphospholipid syndrome has been considered the best paper published in 2021.

Related professionals

David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
SILVIA GARTNER TIZZANO

SILVIA GARTNER TIZZANO

Main researcher
Growth and Development
Read more
Luca Basile

Luca Basile

Administration and Management
Microbiology
Read more
Ana  Leon  Espitia

Ana Leon Espitia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.